SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (date of earliest event reported): March 4, 2002
Nabi Biopharmaceuticals
| Delaware | 0-4829-03 | 59-1212264 | ||
|
|
||||
| State or other jurisdiction of incorporation |
Commission File Number | IRS Employer Identification No. |
5800 Park of Commerce Boulevard N.W.,
Boca Raton, Florida 33487
(561) 989-5800
including area code)
Nabi
ITEM 5. OTHER EVENTS.
At the close of business on March 4, 2002, the Company changed its name from “Nabi” to “Nabi Biopharmaceuticals.” The name change was effective upon the filing of a Certificate of Ownership and Merger with the Secretary of State of Delaware resolving to merge a wholly owned subsidiary of the Company into the Company for the sole purpose of changing our name.
The Company’s common stock still trades under the ticker symbol “NABI” on the Nasdaq Stock Market.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Nabi Biopharmaceuticals | ||
| By: /s/ Mark L. Smith | ||
|
|
||
|
Mark L. Smith Senior Vice President, Finance, Chief Financial Officer, Chief Accounting Officer and Treasurer |
Dated: March 5, 2002
2